Comprehensive oncology NGS portfolio
Five next-generation sequencing tests for hereditary cancer risk, somatic tumor profiling and ctDNA analysis, delivered as interpreted reports. No in-house bioinformatics required.
Five tests across the cancer care pathway
Hereditary risk, somatic tumor profiling and plasma ctDNA answer different questions in cancer care.
OncoRisk
31genesGermline risk for patients or families with a suspicious history.
Whole bloodCancerScreen 50
54genesSolid tumor profiling: SNVs, indels and copy-number variants.
FFPE / fresh-frozenctDNA Colorectal
15genesPlasma ctDNA profiling for colorectal cancer.
PlasmactDNA Breast
27genesPlasma ctDNA profiling for breast cancer.
PlasmactDNA Lung
28genesPlasma ctDNA profiling for lung cancer.
PlasmaWhere each test fits
OncoRisk
- Early-onset cancer or a striking family history
- Testing first-degree relatives once a variant is found
- Risk-reducing surgery and enhanced surveillance decisions
- PARP inhibitor eligibility via BRCA1/2, PALB2 and HRR genes
- Lynch syndrome workup: MLH1, MSH2, MSH6, PMS2, EPCAM
CancerScreen 50
- Molecular profiling of solid tumors
- Treatment-related genes: EGFR, KRAS, NRAS, BRAF, ERBB2, PIK3CA, MET, KIT, IDH1/2, ESR1
- Interpretation in the context of tumor type
- Clinical trial options when no approved drug matches
ctDNA panels
- Targeted plasma analysis for colorectal, breast and lung cancer
- Built around the drivers and resistance mechanisms that change management
- Low input: plasma with more than 20 ng of cfDNA
- Low-frequency detection at 0.5% variant allele frequency in reference studies
Side by side
Manufacturer reference specifications from Celemics product sheets (2025).18
| Test | Sample | Genes | Covered region | Target | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| OncoRisk | Whole blood (>50 ng gDNA) | 31 | Whole CDS | 96 Kb | 97.9% | >99% |
| CancerScreen 50 | Fresh-frozen / FFPE tissue | 54 | Whole CDS | 197 Kb | Not specified | Not specified |
| ctDNA Colorectal | Plasma (>20 ng cfDNA) | 15 | Whole CDS | 49 Kb | 100% at 0.5% VAF | 97.9% |
| ctDNA Breast | Plasma (>20 ng cfDNA) | 27 | Whole CDS | 99 Kb | 94.4% at 0.5% VAF | 96.3% |
| ctDNA Lung | Plasma (>20 ng cfDNA) | 28 | Whole CDS (8) + hotspot (20) | 47 Kb | 100% at 0.5% VAF | 100% |
Reference studies: Coriell samples for OncoRisk; Seraseq® ctDNA Reference Material v2 at 0.5% and 1.0% VAF for the ctDNA panels. Every ctDNA panel reached 100% sensitivity at 1.0% VAF. Performance depends on the specimen, workflow and variant.
Genes by panel
Every gene on each panel. The ctDNA panels share core genes including TP53, PIK3CA, KRAS, EGFR, ERBB2 and PTEN.
What your oncology team receives
Physician-ready reports with findings, evidence and clinical context, not a raw variant file.
| Gene | Change | Type | Classification |
|---|---|---|---|
| BRCA1 | c.5266dup | Frameshift dup. | Pathogenic |
| CHEK2 | c.1100del | Frameshift del. | Pathogenic / LP |
Benign and likely-benign variants are not reported.
- ClinVar accession, review status and expert-panel status
- Transcript, protein change, zygosity and gnomAD frequency
- Gene function, inheritance and named syndrome (OMIM)
- Clinical management considerations with PMID citations
- QC summary: coverage, on-target rate and limitations
| Variant class | FDA-approved therapy example |
|---|---|
| SNV | Osimertinib (first-line metastatic setting) |
- Annotated with ClinVar, CIViC and AMP/ASCO/CAP classification
- When no approved drug matches, open trials by NCT ID, phase, biomarker and status
- Methodology, QC metrics and stated limitations
A complete testing pathway for your hospital
- CLIA-certified laboratory operating the full testing pathway in the United States
- Celemics hybrid-capture panel design and target enrichment
- Interpreted reports, so no in-house bioinformatics is required
- Defined panel content and a documented test workflow
- A commitment to reclassify variants as new evidence is published
What the hospital provides
The right specimen, a completed requisition and relevant clinical information. We supply kits, requisitions and logistics.
Turnaround time, pricing and collection-tube specifications will be confirmed at launch.
A four-step pilot
- Step 1
Select panels
Based on clinical demand, specimen access and service scope.
- Step 2
Review sample reports
Complete de-identified reports for your oncology and pathology teams.
- Step 3
Confirm logistics
Tubes, kits, courier schedule, requisitions and result delivery.
- Step 4
Pilot
A time-boxed pilot on an agreed case mix, with a joint review of turnaround and report utility.